In an environment of rapidly evolving lifestyles and personal grooming standards, access to robust insights on promising industries is an asset. One such potential-filled domain is the hyperhidrosis treatment market, poised for consistent growth owing to the increase in prevalence of secondary hyperhidrosis conditions and increased investments in research and development.
This comprehensive market research report provides in-depth analysis of the market trends, key growth drivers, potential challenges and competitive landscape in the hyperhidrosis treatment market. The report substantiates its insights with findings from renowned sources such as the NCBI, and covers potential growth areas like the promising Hyperhidrosis treatment pipeline.
With geographical expansions, new product development, mergers and acquisitions shaping the industry landscape, acquire advantage over others through detailed understanding of these transformations. In an industry where therapeutic advances potentially come with short-term results, let this report guide you in anticipating shifts and seizing opportunities. Let this study be your roadmap to informed decision making in the hyperhidrosis treatment market.
The pandemic has significantly impacted the market. For instance, as per the NCBI study published in January 2021, during the initial phase of the COVID-19 infection, the condition of most of the prolonged cases of hypothermia resulted in fever. Thus, the demand for hyperhidrosis treatment increased initially; however, the market also witnessed an adverse impact. According to the International Hyperhidrosis Society in May 2021, sweat could help prevent the transmission of COVID-19. The organization supports that claim with quotes from experts like dermatologist Adam Friedman of George Washington University, who noted that 'Sweat has some inherent antimicrobial activity.' Therefore, the market witnessed moderate growth during the initial days of the pandemic. However, with the declining cases of COVID-19, the market has started to gain momentum and is expected to witness an upward trend over the forecast period.
The key factors bolstering the growth of the hyperhidrosis treatment market are the rise in the prevalence of secondary hyperhidrosis conditions and the increase in investments in research and development by the market players. According to the NCBI study published in October 2021, in the United States, the prevalence rate of this disorder was estimated to be around 3.0% of the total population. Emotional, psychological, social, and occupational impairment can all be caused by hyperhidrosis.
Some other factors that could potentially impact the market's growth are the promising pipeline for hyperhidrosis treatment, the growing prevalence of depression and anxiety, growing awareness about hyperhidrosis, and the presence of favorable reimbursement policies. For instance, in October 2021, Brickell Biotech Inc. reported positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once-daily topical formulation in patients with primary axillary hyperhidrosis. Thus, the increasing burden of hyperhidrosis and treatment advancements are anticipated to bolster the demand for its treatment, thereby boosting the market's growth.
Geographical expansions, product launches, acquisitions, collaborations, mergers, and partnerships by major players to establish a strong presence positively impact the market. For instance, in April 2021, Fortress Biotech, the partner company of Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to these factors, the market studied is expected to witness growth over the forecast period.
However, short-term results of cosmetic and therapeutic procedures are likely to restrain the growth of the hyperhidrosis treatment market over the forecast period.
Hyperhidrosis Treatment Market Trends
Botulin Toxin A is Expected to Hold the Largest Market Share Over the Forecast PeriodBotulinum toxin type A is a safe and effective treatment for focal hyperhidrosis that lasts longer than topical treatments and does not require invasive surgical procedures. Botulinum toxin injections are most commonly used to treat axillary hyperhidrosis, but they can also be used to treat palmar and plantar disease. Botulinum toxin's effects last six to nine months on average, and treatment is linked to a high satisfaction rate among patients.
AbbVie Inc. owns BOTOX, which is the most researched botulinum toxin in the world. BOTOX has been approved for the treatment of excessive sweating in the underarms in at least 20 countries. It can also be used off-label to treat sweating in the face, feet, and hands. In April 2021, Aquavit Holdings LLC announced that it acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in the United States and Canada. Excessive sweating of the armpits, hands, feet, head, and face (craniofacial) and other relatively small body areas (like under the breasts) can be treated with botulinum toxin A as per the article published by the International Hyperhidrosis Society in October 2020. Botox has been shown to reduce sweating by 82.0% to 87.0% when used to treat excessive sweating under the arms. The effects begin to show up two to four days after treatment, with the full effects usually appearing within two weeks. Dryness lasts four to 12 months on average, but some studies have found that it can last up to 14 months.
Various studies have demonstrated its efficacy in reducing anxiety as well. For instance, according to a study published in the journal Scientific Reports in 2021, people who received Botox injections at four different sites reported significantly fewer signs of anxiety than those who received different treatments for the same conditions. The risk of anxiety was found to be reduced by 22.0% to 72.0% in Botox patients. Hence, the effectiveness of botulinum toxin type A in treating hyperhidrosis and its long-lasting effect is driving the market's growth.
North America is Expected to Hold the Largest Market Share Over the Forecast PeriodNorth America is expected to dominate the overall hyperhidrosis treatment market throughout the forecast period. The growth is owing to factors such as the increasing burden of primary hyperhidrosis, cancer, and cardiovascular disorders, increases in secondary hyperhidrosis, technological advancements, and the presence of key market players in the region.
The high prevalence of primary and secondary hyperhidrosis will increase the adoption of treatment in the region. According to the NCBI research paper published in October 2022, approximately 2.8% of the US population suffers from hyperhidrosis, which is common in patients between 20 to 60 years of age. The high prevalence has increased the adoption of various treatments, such as over-the-counter aluminum chloride hexahydrate 20.0% in the region. Such prevalence will increase the demand for product consumption, thereby increasing the market's growth.
Key product launches, high concentration of market players or manufacturer's presence, acquisition and partnerships among major players, and increasing research and development activities for hyperhidrosis treatment products in the United States will lead to higher adoption of these products. For instance, in April 2021, Fortress Biotech, a partner company of Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to the above-mentioned factors, the market is expected to witness considerable growth over the forecast period.
Hyperhidrosis Treatment Market Competitor AnalysisThe hyperhidrosis treatment market is moderately competitive and consists of several major players. The prominent players in the market are AbbVie, Brickell Biotech, Eli Lilly and Company (Dermira), Advin Healthcare, and Dermavant Scienecs Inc. (Roivant Sci), among others. The companies operating in the market are focusing on R&D investments and fundraising activities to conduct clinical trials that lead to strong product pipelines.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rise in Prevalence of Secondary Hyperhidrosis Condition
4.2.2 Increase in Investments by Market Players in Research and Development
4.3 Market Restraints
4.3.1 Short-term Results of Cosmetic and Therapeutic Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Topical Treatments
5.1.2 Surgical Treatments
5.1.3 Botulin toxin A
5.1.5 Laser Treatments
5.1.6 Other Treatment Types
5.2 By Disease Type
5.2.1 Primary Focal Hyperhidrosis
5.2.2 Secondary Generalized Hyperhidrosis
5.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.3.4 Middle East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle East and Africa
5.3.5 South America
18.104.22.168 Rest of South America
6.1.1 AbbVie Inc. (Allergan PLC)
6.1.2 Brickell Biotech Inc.
6.1.3 Eli Lilly and Company (Dermira)
6.1.4 1315 Capital (miraDry Inc.)
6.1.6 Merz Pharma (Merz Aesthetics)
6.1.7 Dermavant Sciences Inc. (Roivant Sciences)
6.1.8 Advin Health Care
6.1.9 Dermadry Laboratories Inc.
6.1.10 Dermata Therapeutics Inc.
A selection of companies mentioned in this report includes:
- AbbVie Inc. (Allergan PLC)
- Brickell Biotech Inc.
- Eli Lilly and Company (Dermira)
- 1315 Capital (miraDry Inc.)
- Merz Pharma (Merz Aesthetics)
- Dermavant Sciences Inc. (Roivant Sciences)
- Advin Health Care
- Dermadry Laboratories Inc.
- Dermata Therapeutics Inc.